Treatment of prostate cancer cells with CXCL12 prior to immunoprecipitation shows 2.2 to 8.3 folds higher recruitment of TTC7B into CXCR4 complexes in PC3-CXCR4, C4-2B and VCaP cells and 3.5 to 3.6 folds higher recruitment of PI4KIIIα into CXCR4 complexes in PC3-CXCR4 and VCaP cells (Fig. 1A,C,D) suggesting CXCL12 activation of CXCR4 forms a complex with TTC7B and PI4KIIIα in prostate cancer cells. This evidence concerns the gene CXCL12 and prostate carcinoma.